一分钟看懂
这是一项关于多发性骨髓瘤的I 期研究，登记的药物或干预包括KSVCBD injection，当前状态为招募中。登记地点显示中国北京、天津有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
KSVCBD injection · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Biotherapeutic Department of Chinese PLA General Hospital · 北京
- Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University · 北京
- National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chines · 天津
公开的入选条件
- 1. Age 18-75 years (inclusive), any gender.
- 2. Subjects must meet the following diagnostic and treatment criteria:
- 2.1 According to the IMWG 2014 diagnostic criteria, subjects must have a confirmed diagnosis of multiple myeloma and be in a relapsed or refractory state at screening, while meeting all of the following conditions:
- Must have received at least 3 prior lines of MM therapy (including a proteasome inhibitor and an immunomodulatory agent). consecutive cycles of induction chemotherapy, hematopoietic stem cell transplantation, and maintenance therapy are considered as one line
- Must have experienced disease progression during or within 12 months after the most recent anti-myeloma therapy. or the subject must have experienced disease progression within the last 6 months and subsequently shown no response to the most recent line of the
- 2.2 Subjects judged by the investigator to be intolerant to standard therapy may also be included in the study.
- 3. Presence of measurable lesions at screening as determined by any of the following criteria:
- Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dL, or urinary M-protein level ≥ 200 mg/24 hours. or
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07620275；登记信息更新于 2026-09-15。